Challenges & Opportunities for CABG Surgery
Executive Summary
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
You may also be interested in...
Estech: Back From the Brink
Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.
Estech: Back From the Brink
Estech, a small cardiac surgery and surgical ablation company, figured it had its strategy all set: after taking an investment from Boston Scientific, it would ramp up commercialization and, once it hit a certain sales target, would be acquired by BSC. But when Boston itself changed its strategy around the small companies in which it had made investments, Estech found itself in trouble.
Cardica: Rebuilding the Cardiac Surgery Market
The predicted expansion of beating-heart and minimally-invasive cardiac surgery never materialized, a result, some say, of the lack of safe and effective automated anastomotic tools. Cardica believes it has the answer that can at long last grow this market.